Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells $1,083,905.42 in Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Arturo Md Molina sold 13,151 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $82.42, for a total transaction of $1,083,905.42. Following the completion of the sale, the insider owned 84,115 shares of the company’s stock, valued at approximately $6,932,758.30. The trade was a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Arturo Md Molina also recently made the following trade(s):

• On Tuesday, January 27th, Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $82.00, for a total transaction of $410,000.00.
• On Tuesday, January 20th, Arturo Md Molina sold 9,514 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $82.48, for a total transaction of $784,714.72.

Protagonist Therapeutics Stock Down 2.5%

NASDAQ PTGX opened at $79.73 on Friday. The company has a 50-day simple moving average of $86.33 and a two-hundred day simple moving average of $72.53. Protagonist Therapeutics, Inc. has a 12-month low of $33.70 and a 12-month high of $96.54. The firm has a market cap of $4.98 billion, a price-to-earnings ratio of 128.60 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The company had revenue of $4.71 million during the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. Equities analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PTGX has been the subject of a number of analyst reports. Wedbush raised their target price on shares of Protagonist Therapeutics from $70.00 to $86.00 and gave the stock an “outperform” rating in a report on Tuesday, October 28th. Weiss Ratings raised shares of Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, December 24th. BTIG Research reissued a “buy” rating and issued a $82.00 price target on shares of Protagonist Therapeutics in a report on Tuesday, October 28th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday, October 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Protagonist Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $86.77.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC boosted its holdings in Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after acquiring an additional 156 shares in the last quarter. Salomon & Ludwin LLC purchased a new position in shares of Protagonist Therapeutics in the 3rd quarter worth about $29,000. FNY Investment Advisers LLC bought a new position in Protagonist Therapeutics in the 2nd quarter worth about $27,000. Bessemer Group Inc. boosted its stake in Protagonist Therapeutics by 171.0% in the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock worth $28,000 after purchasing an additional 318 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in Protagonist Therapeutics by 138.9% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after purchasing an additional 314 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.